Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Tight liquidity NBB
Cash and receivables cover 16 % of short-term debt in 2024; threshold 65 %.
-
Annual account missing NBB
Fiscal year 2025 was expected before 31 October 2025 and has not been filed.
Financials
Financial year 2024
JEOZIF PHARMA from Schaarbeek, company number BE0892375452, closed financial year 2024 with a result of € 21,263 after tax. For that financial year JEOZIF PHARMA recorded a gross margin of € 30,111 and equity of € 177,451. Compared with financial year 2023, the result moved from € 20,448 to € 21,263. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on November 28, 2024.
€ 177,451
▲ 14% vs 2023
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 21,263
▲ 4% vs 2023
Profit after tax over the fiscal year.
€ 2,872
▼ 44% vs 2023
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2024. Retained profit grew to € 171,251.
Debts at end 2024
None
No bank loans on the last day of the fiscal year.
€ 10,744
▲ € 10,085 vs 2023
Supplier invoices still open on the last day of the fiscal year.
€ 9,907
▼ 37% vs 2023
Taxes, VAT and social contributions still to pay.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | Change 2023 → 2024 | |
|---|---|---|---|---|
| Gross margin | € 36,988 | € 28,876 | € 30,111 | ▲ 4% |
| Profit after taxes | € 21,969 | € 20,448 | € 21,263 | ▲ 4% |
| Equity | € 137,740 | € 156,188 | € 177,451 | ▲ 14% |
| Total debts | € 366,993 | € 346,000 | € 361,456 | ▲ 4% |
| Cash | € 6,219 | € 5,101 | € 2,872 | ▼ 44% |
| Retained profit | € 131,540 | € 149,988 | € 171,251 | ▲ 14% |
| Dividend | € 0 | € 2,000 | € 0 | ▼ 100% |
| Bank debt | € 28,144 | € 0 | € 0 | |
| Balance sheet total | € 504,733 | € 502,188 | € 538,907 | ▲ 7% |
Key figures of JEOZIF PHARMA, fiscal years 2022 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 31 October 2025.
What happened to JEOZIF PHARMA?
What happened at JEOZIF PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2024: profit of € 21,263 (▲ 4% vs 2023). filed late Source: NBB ↗
- Start of the company according to the CBE. KBO
In short
From € 21,969 profit in 2022 to € 21,263 profit in 2024.
Paid € 27,313 in corporate taxes since 2022.
Best year ever: 2022, with € 21,969 profit.
Paid out € 2,000 in dividends to the owners in total.
A new publication or filing at JEOZIF PHARMA? We notify you, reason included.
Follow JEOZIF PHARMADatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
Behind JEOZIF PHARMA is Jeosif Butros. It owns 100% of D-Pharma itself.
Directors
According to the 2024 annual accounts
Jeosif Butros
Manager
Establishments
Establishment units
Physical locations of this company
Jan Stobbaertslaan 10
1030 Schaarbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0892.375.452
- VAT number
- BE 0892.375.452
- Registered office
- Jan Stobbaertslaan 10, 1030 Schaarbeek
- Names & denominations
- JEOZIF PHARMA
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 September 2007
- Peppol
- Active · Active since 31 Dec 2025
- Activities · NACE
Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies
Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering